

November 8, 2018



# Medicine Man Technologies Reports Record Quarterly Operating Revenue of \$4.6M, Quarterly Investment Related Income of \$2.6M, and its Third Consecutive Quarter Profit Posting of \$4.9M

**DENVER, CO / ACCESSWIRE / November 8, 2018** Medicine Man Technologies Inc. (OTCQB: [MDCL](#)) ("Medicine Man Technologies" or "Company"), one of the United States' leading cannabis branding and consulting companies today provided financial results for the quarter ended September 30, 2018.

During the three months ending September 30, 2018, the Company generated operating revenues of \$4,647,163, an increase of approximately 400% as compared to revenues of \$928,264 in the three months ending September 30, 2017. Other income for the three months ending September 30, 2018 increased to \$2,605,672 as compared with losses in the three months ending September 30, 2017 of <\$165,881>. This substantial increase in the Company's overall revenue stream is related to both internal revenue source growth as well as the Company's Canada House Wellness (CHV) Master Licensing Agreement as announced in July of this year.

The Company reported cost of goods and services totaling \$459,280 during the three months ended September 30, 2018. This is compared to \$297,185 during the same time period in 2017. The increase is primarily due to an increase in overall product sales volume.

Operating expenses during the three months ended September 30, 2018, increased by \$892,051 to \$1,824,876 over the prior period of \$950,825, ended September 30, 2017 noting \$673,500 of this expense increase was related to stock compensation.

The Company reported net income related to the three months ending September 30, 2018 of \$4,950,679 or \$0.18 per share as compared with losses of <\$485,627> as related to the three months ending September 30, 2017.

Year to date total income performance increased dramatically to \$9,917,476 for the nine months ending September 30, 2018 as compared to total income of \$2,585,479 as reported for the nine months ending September 30, 2017.

Year to date net income performance increased dramatically to \$5,157,717 or \$0.19 per share for the nine months ending September 30, 2018 as compared to losses of <\$4,868,859> or <\$0.22> per share as reported for the period ending September 30, 2017.

While the Company continues to grow its organic revenues, the Master Licensing Agreement as noted was responsible for a large portion of this revenue growth however, organic growth still increased to \$3,782,921 in the nine months ended September 30, 2018 from \$2,485,479 as related to the nine months ended September 30, 2017.

"We continue to prove out our path to profitability model and demonstrate strong organic as well as one-time revenue growth as we conclude our third consecutive profitable quarter, followed closely by achieving our seventh quarter of consecutive revenue growth," Brett Roper, Medicine Man Technologies' co-founder, and CEO stated. "We are also exploring other globally sourced master license agreement opportunities and are pleased to also acknowledge our Company's move to QX status on the OTC markets as achieved this past September."

Joshua Haupt, Medicine Man Technologies Chief Operating Officer added, "With this exceptional progress and the lack of any debt, I am very excited about what our future holds as we move into 2019. With our Grow Ohio Pharma client's Zanesville Ohio facility coming online coupled with our Calypso client's Erie Pennsylvania facility planned for operational status in the second quarter of 2019, we have many new opportunities ahead for the Company. I also look forward to attending next week's MJ Business Conference in Las Vegas Nevada and connecting with my many colleagues in the industry."

Andy Williams, Medicine Man Technologies' Chairperson of the Board stated, "With the Colorado Governorship going to Jared Polis, a seasoned advocate of the cannabis industry and states' rights this provides new momentum for the continuation of the industry's success which has continued to bolster the state's economy, generating record-setting revenue and creating thousands of jobs for the citizens of Colorado. As a result of regulatory advancements

made by legislative bodies on the local, federal and international levels, the national cannabis market place continues to expand as further evidenced by this week's election cycle. Medicine Man Technologies' multi-jurisdictional business model has positioned the Company to leverage this dramatic growth nationally setting a clear path to Colorado based public company ownership in 2019."

### **Conference Call Instructions**

The Company will host a conference call on Friday, November 9, 2018 at 10:30 AM Eastern Time to discuss the results.

### **Participant Dial-In Numbers:**

**TOLL-FREE 1- 877-407-9716**

**TOLL/INTERNATIONAL 1-201-493-6779**

**Participants should request the Medicine Man earnings call or provide confirmation code 13684963.**

Investors are invited to listen via webcast available on the Medicine Man Technologies investor section of the Company's website at <http://www.medicinemantechnologies.com/investor-calendar.html>. Please visit the website 15 minutes prior to the call to register, download, and install any necessary audio software. For interested individuals unable to join the conference call, a replay of the call will be available through November 23, 2018, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13684963. The online archive of the webcast will be available on the investor section of the Company's website for 30 days following the call.

Brett Roper, Co-Founder and Chief Executive Officer of Medicine Man Technologies, and Jonathan Sandberg, Chief Financial Officer, will be answering shareholder questions at the conclusion of the call. Should you have questions prior to the conference call please send an email to [MDCL@kcsa.com](mailto:MDCL@kcsa.com) with 'MDCL Question' in the subject line. Management will answer as many questions as time will allow.

### **About Medicine Man Technologies, Inc.**

Established in March 2014, the Company secured its first client/licensee in April 2014. To date, the Company has provided guidance for several clients that have successfully secured licenses to operate cannabis businesses within their state. The Company currently has or has had active clients in California, Iowa, Oregon, Colorado, Nevada, Illinois, Michigan, Oklahoma, Missouri, Arkansas, Pennsylvania, Florida, Ohio, Maryland, New York, Massachusetts, Puerto Rico, Canada, Australia, Germany, and South Africa. We continue to focus on working with clients to 1) utilize its experience, technology, and training to help secure a license in states with newly emerging regulations, 2) deploy the Company's highly effective variable capacity constant harvest cultivation practices through its deployment of Cultivation MAX, and eliminate the liability of single grower dependence, 3) avoid the costly mistakes generally made in start-up, 4) stay engaged with an ever expanding team of licensees and partners, all focused on quality and safety that will "share" the ever-improving experience and knowledge of the network, and 5) continuing the expansion of our Brands Warehouse concept through entry into industry based cooperative agreements and pursuing other acquisitions as they prove suitable to our overall business development strategy.

### **Safe Harbor Statement**

This press release may contain forward-looking statements which are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues and any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the Securities and Exchange Commission. Among other matters, the Medicine Man Technologies may not be able to sustain growth or achieve profitability based on many factors including, but not limited to, general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in the expansion of our existing and new service lines, noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long-term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations where we will be providing services, the impact of which

cannot be predicted at this time.

To be added to the Medicine Man email distribution list, please email [MDCL@kcsa.com](mailto:MDCL@kcsa.com) with MDCL in the subjectline.

For more information, visit us at [www.medicinemantechnologies.com](http://www.medicinemantechnologies.com); [www.threalight.com](http://www.threalight.com)

**Contact Information:**

Brett Roper via  
[info@medicinemantechnologies.com](mailto:info@medicinemantechnologies.com)  
 Telephone (303) 371-0387

**MEDICINE MAN TECHNOLOGIES, INC.**  
**CONSOLIDATED BALANCE SHEETS**  
 Expressed in U.S. Dollars

	<b>September 30, 2018</b>	<b>December 31, 2017</b>
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 529,674	\$ 748,715
Accounts receivable	1,009,170	461,343
Accounts receivable - related party	53,839	25,719
Litigation receivable	990,864	-
Short-term note receivable, net of allowance	188,550	191,111
Inventory	441,960	106,091
Other assets	34,582	42,819
Total current assets	<u>3,248,639</u>	<u>1,575,798</u>
Non-current assets		
Fixed assets, net accumulated depreciation of \$131,405 and \$82,038	\$ 84,493	\$ 150,047
Intangible assets, net accumulated amortization of \$12,275 and \$7,388	82,825	87,712
Goodwill	12,304,306	9,304,306
Investment	5,260,840	-
Other non-current assets	26,317	14,500
Total non-current assets	<u>17,758,781</u>	<u>9,556,565</u>
Total assets	<u>\$21,007,420</u>	<u>\$11,132,363</u>
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities		
Accounts payable	\$ 172,360	\$ 123,251
Accounts payable - related party	53,000	155,177
Accrued expenses	47,684	-
Other liabilities	-	56,495
Total current liabilities	<u>273,044</u>	<u>334,923</u>
Long-term liabilities		
Note payable - related party	\$ -	\$ 58,280
Total long-term liabilities	<u>-</u>	<u>58,280</u>
Total liabilities	<u>273,044</u>	<u>393,203</u>
Commitments and contingencies, note 13		
Shareholders' equity		
Common stock \$0.001 par value. 90,000,000 authorized, 27,578,310 and 22,991,137 were issued and outstanding September 30, 2018 and December 31, 2017, respectively	\$ 28,766	\$ 23,113
Additional paid-in capital	20,283,174	13,997,441
Additional paid-in capital - Warrants	2,054,369	3,508,256
Accumulated other comprehensive (loss)	-	-
Retained earnings	<u>(1,631,933)</u>	<u>(6,789,650)</u>
Total shareholders' equity (deficit)	<u>20,734,376</u>	<u>10,739,160</u>

Total liabilities and stockholders' equity

\$21,007,420 \$11,132,363

**MEDICINE MAN TECHNOLOGIES, INC.**  
**CONSOLIDATED STATEMENT OF COMPREHENSIVE (LOSS) AND INCOME**

For the Three and Nine Months Ended September 30, 2018 and 2017

Expressed in U.S. Dollars

	<u>Three Months Ended</u> <u>September 30,</u>		<u>Nine Months Ended</u> <u>September 30,</u>	
	<u>2018</u>	<u>2017</u>	<u>2018</u>	<u>2017</u>
<b>Operating revenues</b>				
Product sales, net	\$ 280,737	\$ 278,495	\$ 797,381	\$ 506,900
Product sales - related party, net	143,761	61,768	425,499	184,711
Litigation revenue	180,000	-	1,015,154	-
Cultivation Max	88,933	-	304,090	-
Master licensing fees	3,518,322	-	3,518,322	-
Licensing fees	237,700	347,504	663,414	848,816
Consulting fees	163,147	238,480	486,747	805,086
Reimbursements	29,840	-	72,920	-
Services - related party	4,479	-	13,437	-
Seminars and others	244	2,017	4,279	6,239
Total revenue	<u>4,647,163</u>	<u>928,264</u>	<u>7,301,243</u>	<u>2,351,752</u>
<b>Cost of goods and services</b>				
Cost of goods and services	\$ 421,055	\$ 282,894	\$ 1,091,386	\$ 694,018
Cost of goods and services - related party	38,225	14,291	121,808	40,327
Total cost of goods and services	<u>459,280</u>	<u>297,185</u>	<u>1,213,194</u>	<u>734,345</u>
<b>Gross profit</b>	<u>\$ 4,187,883</u>	<u>\$ 631,079</u>	<u>\$ 6,088,049</u>	<u>\$ 1,617,407</u>
<b>Operating expenses</b>				
General and administrative	\$ 170,117	\$ 331,764	\$ 417,467	\$ 735,018
Professional services	177,103	144,796	657,694	384,278
Acquisition costs	-	42,600	-	141,301
Stock based compensation expenses	837,500	164,000	837,500	4,644,318
Officers and directors bonuses	145,104	90,823	196,157	90,823
Advertising	32,110	49,592	109,650	136,436
Conference and travel expenses	57,595	-	183,530	-
Salaries	423,347	127,250	1,144,567	220,365
Total operating expenses	<u>\$ 1,842,876</u>	<u>\$ 950,825</u>	<u>\$ 3,546,565</u>	<u>\$ 6,352,539</u>
<b>Income from operations</b>	<u>\$ 2,345,007</u>	<u>\$ (319,746)</u>	<u>\$ 2,541,484</u>	<u>\$ (4,735,132)</u>
<b>Other income/expense</b>				
Interest (income)	\$ (7,562)	\$ (7,562)	\$ (22,439)	\$ (22,439)
Net loss on derivative liability	-	136,088	-	4,706
Interest expense related to convertible notes	-	22,636	-	66,965
Loss on sales of assets	-	-	4,316	-
Loss on management fee contracts	-	-	-	70,257
Net loss on available for sale securities	-	14,719	-	14,457
Unrealized (gain)/loss on investments	(2,598,110)	-	(2,598,110)	(219)
Total other expense	<u>(2,605,672)</u>	<u>165,881</u>	<u>(2,616,233)</u>	<u>133,727</u>
<b>Net (loss) income</b>	<u>\$ 4,950,679</u>	<u>\$ (485,627)</u>	<u>\$ 5,157,717</u>	<u>\$ (4,868,859)</u>
<b>Earnings per share attributable to common shareholders:</b>				
Basic and diluted (loss)/earnings per share	<u>\$ 0.18</u>	<u>\$ (0.02)</u>	<u>\$ 0.19</u>	<u>\$ (0.22)</u>
Weighted average number of shares outstanding - basic and diluted	<u>27,578,310</u>	<u>21,883,853</u>	<u>27,578,310</u>	<u>21,883,853</u>
Other comprehensive (loss), net of tax				
Net unrealized (loss) on available for sale securities	-	-	-	-
Total other comprehensive income (loss), net of tax	-	-	-	-
<b>Comprehensive (loss) gain</b>	<u>\$ 4,950,679</u>	<u>\$ (485,627)</u>	<u>\$ 5,157,717</u>	<u>\$ (4,868,859)</u>

**MEDICINE MAN TECHNOLOGIES, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
For the Nine Months Ended September 30, 2018 and 2017  
Expressed in U.S. Dollars

	<u>2018</u>	<u>2017</u>
<b>Cash flows from operating activities</b>		
Net income for the period	\$ 5,157,717	\$(4,868,859)
Adjustments to reconcile net income to net cash provided by operating activities		
Loss (gain) on investment, net	-	4,706
Stock based compensation	837,500	4,644,318
Depreciation and amortization	54,253	43,650
Changes in operating assets and liabilities		
Proceeds from note receivable	2,561	(22,439)
Accounts receivable	(1,566,811)	(373,902)
Inventory	(335,869)	(87,685)
Other assets	(3,580)	(65,331)
Accounts payable and other liabilities	(61,879)	68,490
<b>Net cash earned (used) from operating activities</b>	<u>4,083,892</u>	<u>(637,052)</u>
<b>Cash flows from investing activities</b>		
Sale of assets	16,187	(242,685)
Short term debt	(58,280)	-
Acquisition investment	-	233,357
Investment proceeds	(5,260,840)	-
AFS securities investment, net	-	4,305
<b>Net cash earned from investing activities</b>	<u>(5,302,933)</u>	<u>(5,023)</u>
<b>Cash flows from financing activities</b>		
Sale of common stock	1,000,000	1,058,658
Cash raised by sale of convertible debt	-	179,777
<b>Net cash earned from financing activities</b>	<u>1,000,000</u>	<u>1,238,435</u>
Net decrease in cash and cash equivalents	(219,041)	576,360
Cash and cash equivalents - beginning of period	748,715	351,524
<b>Cash and cash equivalents - end of period</b>	<u>\$ 529,674</u>	<u>\$ 927,884</u>

**SOURCE:** Medicine Man Technologies Inc.